Screener
Cytek Biosciences, Inc. CTKB Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053496
FAQ
- What is Cytek Biosciences, Inc.'s total equity?
- Cytek Biosciences, Inc. (CTKB) reported total equity of $321.95M in Q2 2026.
- How has Cytek Biosciences, Inc.'s total equity changed year-over-year?
- Cytek Biosciences, Inc.'s total equity decreased by 14.7% year-over-year, from $377.56M to $321.95M.
- What is the long-term trend for Cytek Biosciences, Inc.'s total equity?
- Over 5 years (2020 to 2025), Cytek Biosciences, Inc.'s total equity has grown at a 84.4% compound annual growth rate (CAGR), from -$16.03M to $341.74M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Cytek Biosciences, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude